Expert Commentary Questions HSK21542 Efficacy Claims for Chronic Kidney Disease-Associated Pruritus
Key Insights
A critical commentary challenges claims of superior efficacy and safety for HSK21542 in treating chronic kidney disease-associated pruritus (search), noting the Phase II trial data do not demonstrate significant benefit over placebo.
The 0.3 μg/kg dose showed comparable safety to placebo (76.7% vs 73.3% adverse events) rather than superior safety, while the higher 0.6 μg/kg dose demonstrated statistically significant worse outcomes compared to placebo.
Cross-trial comparisons with difelikefalin studies are deemed potentially misleading due to different patient populations and study conditions, highlighting the need for more rigorous evidence before establishing HSK21542's therapeutic role.
A critical commentary published in Frontiers in Pharmacology raises significant concerns about the interpretation and reporting of HSK21542 Phase II trial results for chronic kidney disease-associated pruritus (search) (CKD-aP (search)), challenging claims of superior efficacy and safety made in the original study by Pan et al.
Efficacy Claims Under Scrutiny
The commentary, authored by researchers at Northwell Health, argues that the data do not demonstrate significant benefit of HSK21542 0.3 μg/kg over placebo, contradicting the original study's claims of "superior efficacy." The experts emphasize that the results fail to show statistical difference between the treatment and placebo groups, making the superior efficacy assertion potentially misleading.
The analysis reveals that 62.1% of patients in the HSK21542 0.3 μg/kg group achieved ≥3-point improvement on the Worst Itching Numerical Rating Scale (WI-NRS) at 12 weeks. However, the commentators stress that without demonstrating statistical significance versus placebo, such response rates cannot support superiority claims.
Safety Profile Reassessment
The commentary also disputes claims of superior safety for HSK21542. The incidence of treatment-emergent adverse events in the 0.3 μg/kg group was 76.7%, compared to 73.3% in the placebo group. The experts note that while this comparable safety profile is reassuring, it does not constitute "superior" safety as claimed in the original study.
High-Dose Concerns Highlighted
A particularly concerning finding involves the higher 0.6 μg/kg dose, which showed statistically significant worse outcomes compared to placebo. The group difference was +1.03 points versus placebo, with a 95% confidence interval of +0.01 to +2.07. The confidence interval excludes zero, indicating a statistically significant inferior result for the high dose.
The commentators criticize the original authors for understating these findings, describing the 0.6 μg/kg effect as merely "less pronounced" rather than acknowledging the statistically significant worse performance compared to placebo. This suggests a possible U-shaped dose-response relationship that warrants further investigation.
Cross-Trial Comparison Concerns
The commentary raises red flags about comparisons made between HSK21542 results and difelikefalin Phase 3 KALM-1 and KALM-2 studies. While the original authors reported that HSK21542 showed higher response rates (62.1%) compared to difelikefalin studies (49.1% and 53.4% respectively), the commentators warn that such cross-trial comparisons can be misleading without proper statistical adjustment for different patient populations and study conditions.
The experts also question analogies drawn between HSK21542 and difelikefalin dose-response patterns, noting that difelikefalin showed significant benefit or trends toward benefit at all tested doses, unlike HSK21542's lack of efficacy across dose groups.
Implications for Future Research
The commentary concludes that while HSK21542 could be an interesting therapeutic candidate for CKD-aP (search), the evidence from this Phase II study is insufficient to prove superior efficacy and safety. The experts call for more rigorous reporting standards and caution against inadvertent misstatements that could mislead the scientific community and patients.
The authors recommend that future studies address these methodological concerns and provide clearer evidence before establishing HSK21542's role in managing chronic kidney disease-associated pruritus (search). They emphasize that accurate reporting with substantiated claims will ultimately benefit both the scientific community and patients by setting the stage for credible and reproducible findings in future trials.